OraSure Technologies Inc Stock Downgraded (OSUR)
- Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, ORASURE TECHNOLOGIES INC's return on equity significantly trails that of both the industry average and the S&P 500.
- Net operating cash flow has remained constant at -$7.67 million with no significant change when compared to the same quarter last year. This quarter, ORASURE TECHNOLOGIES INC's cash flow growth rate has remained relatively unchanged and is slightly below the industry average.
- ORASURE TECHNOLOGIES INC has improved earnings per share by 44.4% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. However, we anticipate underperformance relative to this pattern in the coming year. During the past fiscal year, ORASURE TECHNOLOGIES INC continued to lose money by earning -$0.20 versus -$0.29 in the prior year. For the next year, the market is expecting a contraction of 25.0% in earnings (-$0.25 versus -$0.20).
- The gross profit margin for ORASURE TECHNOLOGIES INC is rather high; currently it is at 65.71%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -23.92% is in-line with the industry average.
- The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Health Care Equipment & Supplies industry average. The net income increased by 44.9% when compared to the same quarter one year prior, rising from -$10.23 million to -$5.63 million.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts